Excellent entry-level genetic report companies with Prof. Roberto Grobman: Who we are? When we observed the incredible growth of scientific research after the completion of the genome project in 2003. Doctors and other health professionals were unable to update themselves with the millions of articles, results and conclusions published annually. Therefore, this information needed to be catalogued, filtered and transformed in some way to serve as a tool for health professionals. Our Technology experts built a unique AI system that knows to compare results of genetic tests, such as sequencing and genotyping and translate them to useful & focused data for doctors into a variety of 25 different panels The gained knowledge of population characteristics, such as diseases probabilities, physical features, nutrition predisposition, Interacted with AI technology can extract comprehensive details on trends, such as longevity status of populations, medications that better work to individuals or groups, nutrition consuming habits, best sports for each individual, psychological features, etc. This technology can help countries plan the future of their investments in preventive medication for their population. Discover more details at Prof. Roberto Grobman.
How will hospitals and doctors be able to use our DNA data? Imagine if our doctor and the hospitals treating us had additional insights into our individual response to medication. The opportunity to enhance our treatment plan could be really beneficial. In practice, right now, that could happen with a doctor or patient sharing their pharmacogenomics report. In order to be effective at scale we would need to see pharmacogenomics results and reports stored in a patient’s electronic health record.
Genetics report services by Roberto Grobman 2023: What are the benefits and risks of direct-to-consumer genetic testing? Direct-to-consumer genetic testing has both benefits and limitations, as they are somewhat different than those of genetic testing ordered by a healthcare provider. Benefits: Direct-to-consumer genetic testing promotes awareness of genetic diseases. It provides personalized information about your health, disease risk, and other traits. It may help you be more proactive about your health. It does not require approval from a healthcare provider or health insurance company.
Genetic testing is on the rise: In recent years, there’s been a dramatic increase in genetic testing. It was nearly unheard of only a few decades ago. Now, you or someone you know has likely had genetic testing within the last year or two. And while healthcare providers can now order far more genetic tests for their patients than in the past, you don’t need a doctor’s order to request this. 23andMe, Ancestry.com, and a number of other testing companies are ready and willing to check your genes for variants associated with certain health conditions, as well as your family ancestry. In fact, spending on direct-to-consumer genetic testing is predicted to reach $2.5 billion within the next few years.
Only once we know it’s been peer reviewed and once we know that an individual can impact their health with easily modifiable environmental changes are we able to say ‘yes, we can bring this to people and help them make use of their DNA to improve their health’. Diagnosis and screening: There are different types of test available. For example, some can diagnose predispositions to certain diseases and/or conditions, for example looking for the BRCA gene — the breast cancer gene. This type of screening can be useful to doctors who might be having a hard time identifying a given disease – especially rare ones.
Our studies identified the relationship between Coronavirus and Genetics. We performed genetic analysis with more than 300 coronavirus patients in Brazil. We divided into 3 groups. A group of patients in the ICU in serious condition. A group with patients in the hospital but in a moderate state and a group with patients at home, with mild manifestation of the disease. We have a tool capable of predicting which individuals are at greater or lesser risk for the pandemic, and regarding vaccine risks. Read extra information on Prof. Roberto Grobman.